Document Detail

Danazol in the treatment of myelodysplastic syndromes.
MedLine Citation:
PMID:  3319676     Owner:  NLM     Status:  MEDLINE    
20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only with an increase in platelet count. Responses were short-lived and lacked clinical significance. No patients with anemia or leukopenia responded to treatment and none of the 7 patients with a platelet count less than 30 x 10(9)/l responded. Danazol appears to have limited clinical utility in the treatment of MDS. However, occasional patients with thrombocytopenia may benefit.
A C Buzaid; H S Garewal; S M Lippman; B G Durie; S B Katakkar; B R Greenberg
Related Documents :
1451646 - Phase i trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapa...
14504056 - Phase ii study of pemetrexed disodium (alimta) administered with oral folic acid in pat...
1823826 - Long-term results of [131i]metaiodobenzylguanidine treatment of refractory advanced neu...
15752306 - Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
21235836 - How often does patient-ventilator asynchrony occur and what are the consequences?
16428186 - Autoantibodies against inner ear proteins in patients with delayed endolymphatic hydrop...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  39     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  1987 Oct 
Date Detail:
Created Date:  1988-02-20     Completed Date:  1988-02-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  346-8     Citation Subset:  IM    
Arizona Cancer Center, Tucson.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Danazol / adverse effects,  therapeutic use*
Myelodysplastic Syndromes / drug therapy*
Pregnadienes / therapeutic use*
Reg. No./Substance:
0/Pregnadienes; 17230-88-5/Danazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  B-cell chronic lymphocytic leukaemia with aberrant expression of CD8 antigen.
Next Document:  Primary splenic hairy cell leukaemia: a case report and review of the literature.